- Home
- PRTC vs XERS Comparison
PRTC vs XERS Comparison
Compare PRTC & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- XERS
- Stock Information
- Founded
- PRTC 2015
- XERS 2005
- Country
- PRTC United States
- XERS United States
- Employees
- PRTC N/A
- XERS N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- PRTC Health Care
- XERS Health Care
- Exchange
- PRTC Nasdaq
- XERS Nasdaq
- Market Cap
- PRTC 413.5M
- XERS 752.7M
- IPO Year
- PRTC N/A
- XERS 2018
- Fundamental
- Price
- PRTC $17.80
- XERS $5.11
- Analyst Decision
- PRTC Buy
- XERS Strong Buy
- Analyst Count
- PRTC 1
- XERS 6
- Target Price
- PRTC $45.00
- XERS $6.25
- AVG Volume (30 Days)
- PRTC 5.3K
- XERS 2.0M
- Earning Date
- PRTC 08-27-2025
- XERS 08-07-2025
- Dividend Yield
- PRTC N/A
- XERS N/A
- EPS Growth
- PRTC N/A
- XERS N/A
- EPS
- PRTC 0.21
- XERS N/A
- Revenue
- PRTC $4,828,000.00
- XERS $222,551,000.00
- Revenue This Year
- PRTC $35.98
- XERS $35.03
- Revenue Next Year
- PRTC $115.38
- XERS $18.31
- P/E Ratio
- PRTC $7.93
- XERS N/A
- Revenue Growth
- PRTC 44.98
- XERS 29.88
- 52 Week Low
- PRTC $13.30
- XERS $2.10
- 52 Week High
- PRTC $25.00
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- PRTC 48.68
- XERS 61.48
- Support Level
- PRTC $17.48
- XERS $4.62
- Resistance Level
- PRTC $18.30
- XERS $5.39
- Average True Range (ATR)
- PRTC 0.45
- XERS 0.21
- MACD
- PRTC 0.02
- XERS 0.07
- Stochastic Oscillator
- PRTC 68.48
- XERS 71.72
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).